TG Therapeutics
TGTX
175 hedge funds and large institutions have $1.63B invested in TG Therapeutics in 2020 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 66 increasing their positions, 37 reducing their positions, and 22 closing their positions.
156% more capital invested
Capital invested by funds: $639M → $1.63B (+$995M)
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
141% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 22
79% more call options, than puts
Call options by funds: $41.9M | Put options by funds: $23.4M
78% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 37
21% more funds holding
Funds holding: 145 → 175 (+30)
8.73% more ownership
Funds ownership: 59.23% → 67.96% (+8.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$50.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$38.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$24.7M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$24.2M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$23.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$27M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$8.91M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$7.87M |
| 4 |
AC
Armistice Capital
New York
|
-$7.56M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$3.28M |
TGTX Hedge Fund Activity: Q2 2020 in Review
175 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2020, worth a combined $1.63B — up 156% from $639M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new TGTX positions and 22 closed out — a net gain of 31 holders — while 66 added to existing stakes and 37 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $50.4M. The largest seller was Citadel Advisors, cutting an estimated $27M.
- 175 institutional investors held TG Therapeutics (TGTX) as of Q2 2020, up from 145 in Q1 2020.
- Funds reported $1.63B of TG Therapeutics stock for Q2 2020, up 156% quarter-over-quarter.
- 53 funds opened new TG Therapeutics positions in Q2 2020 and 22 closed out, a net change of +31 holders.
- The largest TG Therapeutics buyer in Q2 2020 was Fidelity Investments, an estimated $50.4M added.
- The largest TG Therapeutics seller in Q2 2020 was Citadel Advisors, an estimated $27M sold.
Based on aggregated 13F filings for Q2 2020.